LEXICON GENETICS INITIATES PROJECT WITH ODYSSEY THERA

Odyssey Thera announced an agreement with Lexicon Genetics to characterize the pathway activity of certain Lexicon compounds in human cells. The announcement marks the fifth such agreement for Odyssey Thera. Odyssey Thera's protein-fragment complementation assay strategy allows for the on-pathway and off-pathway activities of compounds to be visualized and quantified directly in living human cells. Each of hundreds of assays reports on the sub-cellular activity of a compound at a particular node or branch of a biochemical pathway.

()a href="http://biz.yahoo.com/prnews/050620/sfm028.html?.v=15" target="_blank">Yahoo News